U.S. biotech is a sizzling decide for Goldman Sachs , which mentioned the sector affords traders some “very attractive” entry factors. Luke Barrs, head of elementary fairness, EMEA at Goldman Sachs Asset Management, advised CNBC there’s a “transformational change” occurring in healthcare, significantly in genomic know-how, a creating space of medication that may personalize remedies to sufferers. Barrs flagged that the SPDR S & P Biotech ETF ( XBI ) was “underperforming very materially versus the broader market.” XBI is down over 40% this yr, and has slipped round 53% over the past 12 months. The S & P 500 , by comparability, is down 21% year-to-date and 11.7% on a 12-month timeframe. Some corporations within the sector have “immediate challenges,” in line with Barrs, similar to creating medication to be authorised by regulators, which is pricey. However, he added: “A third of that universe is trading below cash on balance sheet, so you’re looking at companies in negative enterprise value position. That seems like a very attractive entry point, if you buy into the long-term growth story.” Such corporations are ripe for takeover, Barrs mentioned. “If you think about the exit strategy for some of these businesses, clearly the opportunity for M & A in this space — where large pharma companies could step in and acquire some of these unique and new technologies — is very attractive.” The 12 largest prescribed drugs corporations presently have round $600 billion in money on their steadiness sheets, Barrs added. “The large pharma industry could easily come in and take out a lot of those new unique technologies, giving you a very interesting upside exit point, if you are committed to some of those new and unique technologies.” Other banks famous alternatives in biotech corporations earlier this month . Piper Sandler analyst Christopher Raymond pointed to Cogent Biosciences as his favourite “under-the-radar” small cap decide, with an chubby score, whereas Morgan Stanley’s Matthew Harrison likes BioMarin Pharmaceutical . – CNBC’s Christina Cheddar Berk contributed to this report.